Business Context and Reporting Period
This Form 8-K Current Report was filed by Personalis, Inc. on May 12, 2026. The report details a significant regulatory development regarding the company's ultrasensitive NeXT Personal test.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific operational event rather than financial performance.
Material Changes
On May 12, 2026, the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostics Program expanded Medicare coverage for Personalis's NeXT Personal test. The expansion specifically includes immunotherapy monitoring for patients with late-stage solid tumors.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of risks and contingencies beyond the announcement of the coverage expansion. No unusual items were reported.
Investor Verification Checklist
- Confirm the effective date of the new Medicare coverage for immunotherapy monitoring.
- Verify the specific clinical criteria for "late-stage solid tumors" under the new coverage policy.
- Assess the potential revenue impact of this coverage expansion on the NeXT Personal test.
- Review subsequent press releases or 10-Q filings for updated financial projections related to this event.